Insulet Co. (NASDAQ:PODD) Shares Sold by Revolve Wealth Partners LLC

Revolve Wealth Partners LLC trimmed its position in shares of Insulet Co. (NASDAQ:PODD) by 8.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,452 shares of the medical instruments supplier’s stock after selling 127 shares during the period. Revolve Wealth Partners LLC’s holdings in Insulet were worth $379,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Baillie Gifford & Co. boosted its position in shares of Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Mizuho Securities USA LLC boosted its holdings in Insulet by 5,928.1% in the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after purchasing an additional 320,416 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after buying an additional 163,388 shares during the last quarter. Finally, Clearbridge Investments LLC grew its position in shares of Insulet by 6.0% in the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after buying an additional 75,526 shares during the last quarter.

Insulet Stock Down 1.6 %

PODD stock opened at $275.89 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company’s 50 day simple moving average is $267.55 and its 200-day simple moving average is $236.30. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $282.87. The firm has a market capitalization of $19.35 billion, a PE ratio of 47.24, a P/E/G ratio of 3.50 and a beta of 1.22.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. During the same quarter last year, the business posted $0.71 earnings per share. Equities analysts expect that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Canaccord Genuity Group lifted their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Wells Fargo & Company upped their target price on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Finally, TD Cowen raised their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $272.81.

Insider Activity at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.